Mucin 16 Rabbit Polyclonal Antibody

Mucin 16 Rabbit Polyclonal Antibody

Size1:50μl Price1:$118
Size2:100μl Price2:$220
Size3:500μl Price3:$980
SKU: APRab14240 Category: Polyclonal Antibody Tags: , , ,

Datasheet

Summary

Production Name

Mucin 16 Rabbit Polyclonal Antibody

Description

Rabbit Polyclonal Antibody

Host

Rabbit

Application

WB,IHC

Reactivity

Human,Rat,Mouse

 

Performance

Conjugation

Unconjugated

Modification

Unmodified

Isotype

IgG

Clonality

Polyclonal

Form

Liquid

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Buffer

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N.

Purification

Affinity purification

 

Immunogen

Gene Name

MUC16

Alternative Names

MUC16; CA125; Mucin-16; MUC-16; Ovarian cancer-related tumor marker CA125; CA-125; Ovarian carcinoma antigen CA125

Gene ID

94025

SwissProt ID

Q8WXI7

 

Application

Dilution Ratio

WB 1:500-2000;IHC-p 1:50-300

Molecular Weight

 

Background

domain:Composed of three domains, a Ser-, Thr-rich N-terminal domain, a repeated domain containing more than 60 partially conserved tandem repeats of 156 amino acids each (AAs 12061-21862) and a C-terminal transmembrane contain domain with a short cytoplasmic tail.,function:Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.,induction:Up-regulated in ovarian cancer cells.,miscellaneous:Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.,polymorphism:The number of repeats is highly polymorphic.,PTM:Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans.,PTM:Heavily O-glycosylated; expresses both type 1 and type 2 core glycans.,PTM:May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space.,PTM:May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts.,similarity:Contains 14 LRR (leucine-rich) repeats.,similarity:Contains 2 ANK repeats.,similarity:Contains 56 SEA domains.,subcellular location:May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.,subunit:Binds to MSLN. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.,tissue specificity:Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas.,domain:Composed of three domains, a Ser-, Thr-rich N-terminal domain, a repeated domain containing more than 60 partially conserved tandem repeats of 156 amino acids each (AAs 12061-21862) and a C-terminal transmembrane contain domain with a short cytoplasmic tail.,function:Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.,induction:Up-regulated in ovarian cancer cells.,miscellaneous:Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.,polymorphism:The number of repeats is highly polymorphic.,PTM:Heavily N-glycosylated; expresses primarily high mannose and complex bisecting type N-linked glycans.,PTM:Heavily O-glycosylated; expresses both type 1 and type 2 core glycans.,PTM:May be phosphorylated. Phosphorylation of the intracellular C-terminal domain may induce proteolytic cleavage and the liberation of the extracellular domain into the extracellular space.,PTM:May contain numerous disulfide bridges. Association of several molecules of the secreted form may occur through interchain disulfide bridges providing an extraordinarily large gel-like matrix in the extracellular space or in the lumen of secretory ducts.,similarity:Contains 14 LRR (leucine-rich) repeats.,similarity:Contains 2 ANK repeats.,similarity:Contains 56 SEA domains.,subcellular location:May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain.,subunit:Binds to MSLN. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.,tissue specificity:Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas.,

 

Research Area